<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ABSTRACT: First described in 1983, <z:e sem="disease" ids="C0574083" disease_type="Disease or Syndrome" abbrv="">Barth syndrome</z:e> (BTHS) is widely regarded as a rare <z:hpo ids='HP_0001417'>X-linked</z:hpo> <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disease</z:e> characterised by <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> (CM), <z:hpo ids='HP_0003756'>skeletal myopathy</z:hpo>, <z:hpo ids='HP_0001510'>growth delay</z:hpo>, <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and increased urinary excretion of 3-methylglutaconic acid (3-MGCA) </plain></SENT>
<SENT sid="1" pm="."><plain>Fewer than 200 living males are known worldwide, but evidence is accumulating that the disorder is substantially under-diagnosed </plain></SENT>
<SENT sid="2" pm="."><plain>Clinical features include variable combinations of the following wide spectrum: <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> (<z:chebi fb="20" ids="15767">DCM</z:chebi>), <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> (HCM), <z:hpo ids='HP_0001706'>endocardial fibroelastosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EFE</z:e>), left ventricular non-compaction (LVNC), <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo>, <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo>, <z:hpo ids='HP_0005184'>prolonged QTc interval</z:hpo>, <z:hpo ids='HP_0001270'>delayed motor milestones</z:hpo>, proximal <z:hpo ids='HP_0003198'>myopathy</z:hpo>, <z:hpo ids='HP_0001254'>lethargy</z:hpo> and <z:mp ids='MP_0002899'>fatigue</z:mp>, <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (absent to severe; persistent, intermittent or perfectly cyclical), compensatory <z:mp ids='MP_0000220'>monocytosis</z:mp>, recurrent <z:mp ids='MP_0001794'>bacterial</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e>, <z:hpo ids='HP_0003128'>lactic acidosis</z:hpo>, growth and pubertal delay, <z:hpo ids='HP_0011968'>feeding problems</z:hpo>, <z:hpo ids='HP_0001508'>failure to thrive</z:hpo>, episodic diarrhoea, characteristic facies, and <z:hpo ids='HP_0001417'>X-linked</z:hpo> family history </plain></SENT>
<SENT sid="3" pm="."><plain>Historically regarded as a <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disease</z:e>, BTHS is now considered a multi-system disorder which may be first seen by many different specialists or generalists </plain></SENT>
<SENT sid="4" pm="."><plain>Phenotypic breadth and variability present a major challenge to the diagnostician: some children with BTHS have never been neutropenic, whereas others lack increased 3-MGCA and a minority has occult or absent CM </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, BTHS was first described in 2010 as an unrecognised cause of fetal <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Disabling mutations or deletions of the tafazzin (TAZ) gene, located at Xq28, cause the disorder by reducing remodeling of <z:chebi fb="0" ids="28494">cardiolipin</z:chebi>, a principal <z:chebi fb="0" ids="16247">phospholipid</z:chebi> of the inner <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane </plain></SENT>
<SENT sid="7" pm="."><plain>A definitive biochemical test, based on detecting abnormal ratios of different <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> species, was first described in 2008 </plain></SENT>
<SENT sid="8" pm="."><plain>Key areas of differential diagnosis include metabolic and <z:mp ids='MP_0001799'>viral</z:mp> <z:hpo ids='HP_0001638'>cardiomyopathies</z:hpo>, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> diseases, and many causes of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and recurrent male <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriage</z:e> and <z:hpo ids='HP_0003826'>stillbirth</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="28494">Cardiolipin</z:chebi> testing and TAZ sequencing now provide relatively rapid diagnostic testing, both prospectively and retrospectively, from a range of fresh or stored tissues, blood or neonatal bloodspots </plain></SENT>
<SENT sid="10" pm="."><plain>TAZ sequencing also allows female carrier detection and antenatal screening </plain></SENT>
<SENT sid="11" pm="."><plain>Management of BTHS includes medical therapy of CM, cardiac transplantation (in 14% of patients), antibiotic prophylaxis and granulocyte colony-stimulating factor (G-CSF) therapy </plain></SENT>
<SENT sid="12" pm="."><plain>Multidisciplinary teams/clinics are essential for minimising hospital attendances and allowing many more individuals with BTHS to live into adulthood </plain></SENT>
</text></document>